ストックスクリーナーアプリを入手
36.23
1.36%
-0.50
アフターアワーズ：
36.28
0.05
+0.14%
前日終値:
$36.73
開ける：
$36.75
24時間の取引高:
1.21M
Relative Volume:
0.49
時価総額：
$6.29B
収益：
-
当期純損益:
$-354.30M
株価収益率:
-14.36
EPS:
-2.5234
ネットキャッシュフロー:
$-286.27M
1週間 パフォーマンス:
-4.33%
1か月 パフォーマンス:
-8.88%
6か月 パフォーマンス:
-7.53%
1年 パフォーマンス:
+198.93%
1日の値動き範囲:
$36.07
$37.12
1週間の範囲:
$34.91
$38.62
52週間の値動き範囲:
$11.60
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Compare COGT vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
36.23 | 6.13B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2025-11-10 | アップグレード | Stifel | Hold → Buy |
| 2025-11-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2025-10-16 | 開始されました | Stifel | Hold |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-11 | ダウングレード | Needham | Buy → Hold |
| 2024-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 開始されました | Citigroup | Buy |
| 2023-12-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-12-08 | 開始されました | JP Morgan | Overweight |
| 2023-04-28 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-27 | 再開されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-06-28 | 開始されました | Guggenheim | Buy |
| 2021-10-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-09 | 再開されました | Jefferies | Buy |
| 2020-12-23 | 開始されました | Piper Sandler | Overweight |
| 2020-10-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cogent Biosciences Inc (COGT) 最新ニュース
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences (COGT) Q2 Update Highlights Valuation Challenges Amid Strong Cash Reserves - GuruFocus
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses? - Sahm
COGT Maintained by Piper Sandler -- Price Target Raised to $55 - GuruFocus
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Discipline and Rules-Based Execution in COGT Response - Stock Traders Daily
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences | ARS: Annual Report to Security Holders - Moomoo
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G - Stock Titan
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
COGT Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Guggenheim raises Cogent stock price target to $52 on FDA decisions - Investing.com
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
COGENT BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $60 FROM $72 - Bitget
Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7%Should You Sell? - MarketBeat
Cogent Biosciences (COGT) Slides 6.81% to $38.70 as Biotech Risk-Off IntensifiesLate Stage Breakouts - Vinanet
Cogent Biosciences Q2 Loss Widens - Moomoo
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - Investing News Network
Cogent BiosciencesMay Offer Up To $400 Million In Common Stock Through Guggenheim Securities - TradingView
Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines - Stock Titan
Cogent Biosciences (NASDAQ:COGT) Shares Gap DownTime to Sell? - MarketBeat
Cogent Biosciences set to report earnings ahead of FDA decisions By Investing.com - Investing.com Canada
Cogent Biosciences set to report earnings ahead of FDA decisions - Investing.com
Is Cogent Biosciences Inc (COGT) Worth the Risk After Q2 Earnings Miss? GF Score: 25/100 - GuruFocus
Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, vs. FactSet Est of $98M Loss - marketscreener.com
Form 8K Cogent Biosciences Inc For: 10 August By Investing.com - Investing.com Nigeria
Cogent Biosciences Q2 EPS of $(0.52) beats estimates by 8.77% - scanx.trade
Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results - MarketBeat
Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, Vs. FactSet Est of $98M Loss - Moomoo
Cogent Biosciences Q2 loss widens as bezuclastinib FDA deadlines approach - Quiver Quantitative
Cogent Biosciences Q2 net loss widens on higher expenses - TradingView
Cogent Biosciences (COGT) widens Q2 loss but nears FDA decisions on bezuclastinib - Stock Titan
Cogent’s Bezuclastinib Could Reach FDA Decisions in Nov., Dec. - Stock Titan
Cogent Biosciences, Inc. $COGT Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Assenagon Asset Management S.A. Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Loss-Making Cogent Biosciences, Inc. (NASDAQ:COGT) Expected To Breakeven In The Medium-Term - Moomoo
Cogent Biosciences (COGT) Stock Analysis: High Potential with 29.78% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Cogent Biosciences (COGT) Edges Higher as Shares Hold Above Key SupportIV Crush Alert - vinanet.vn
Cogent Biosciences Gains as Investors Revisit Late-Stage Bezuclastinib Catalysts - Quiver Quantitative
Defilade Capital Management L.P. Sells 216,029 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Seven Fleet Capital Management LP Sells 64,700 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Vanguard Capital Management discloses 5.08% Cogent Biosciences (COGT) ownership in 13G filing - Stock Titan
Principal Financial Group Inc. Trims Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Redmile Group LLC Decreases Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Castleark Management LLC Acquires New Position in Cogent Biosciences, Inc. $COGT - MarketBeat
BlackRock (COGT holder) discloses 8.0% ownership in Cogent Biosciences common stock - Stock Titan
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cogent Biosciences Inc (COGT) Institutional Confidence - TradingKey
Cogent Biosciences Inc (COGT) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):